Compliance with good manufacturing practice (“GMP”) is mandatory for all medicinal products that have been granted a marketing authorisation. Likewise, the manufacture of investigational medicinal products must be in accordance with GMP. Advanced therapy medicinal products that are administered to patients under Article 3 of Directive 2001/83/EC (so called “hospital exemption”) must be manufactured under equivalent quality standards to the manufacturing of advanced therapy medicinal products with a marketing authorisation.
Article 5 of Regulation (EC) No 1394/2007 mandates the Commission to draw up guidelines on good manufacturing practice specific to advanced therapy medicinal products ("ATMPs"). Article 63(1) of Regulation (EU) No 536/2014 also empowers the Commission to adopt and publish detailed guidelines on good manufacturing practice applicable to investigational medicinal products.
EC 22.11.2017
EudraLex 22.11.2017
ID 25008 | Last update: 13.11.2025
REACH Authorisation Decisions List of authorisation decisions adopted on the basis of Article 64 of Regula...
Regolamento (UE) 2017/735 della Commissione del 14 febbraio 2017 recante modifica del regolamento (CE) n. 440/2008 che istituisce dei metodi di prova ai sensi del regolamento ...
ID 25419 | 29.01.2026 / In allegato
Rapporto ISTISAN 25/25 - SIN-SEPI -Sistema informativo nazionale per la s...
Testata editoriale iscritta al n. 22/2024 del registro periodici della cancelleria del Tribunale di Perugia in data 19.11.2024
